Blue Fin Capital’s Edwards Lifesciences EW Stock Holding History

Blue Fin Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$237K	Sell	2,623 -97	-4%	-$8.13K	0.03%	156
2026 Q1	$218K	Sell	2,720 -15	-0.5%	-$1.24K	0.04%	149
2025 Q4	$233K	Sell	2,735 -85	-3%	-$6.98K	0.04%	145
2025 Q3	$219K	Buy	2,820 +262	+10%	+$20.5K	0.03%	143
2025 Q2	$200K	Buy	+2,558	New	+$191K	0.03%	144
2024 Q3	–	Sell	-2,576	Closed	-$238K	–	144
2024 Q2	$238K	Buy	+2,576	New	+$228K	0.05%	136

Other funds holding EW

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

Blue Fin Capital's EW Position: Q2 2026 in Review

Blue Fin Capital reduced its Edwards Lifesciences (EW) stake by 3.6% in Q2 2026, selling an estimated $8.13K and leaving 2,623 shares worth $237K. The position accounts for 0.03% of the portfolio, ranked #156.

Blue Fin Capital first reported a position in EW in Q2 2024 and has held it in 6 quarters since. The position peaked at $238K in Q2 2024. 627 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Blue Fin Capital held 2,623 shares of Edwards Lifesciences worth $237K as of Q2 2026.
Blue Fin Capital sold 97 Edwards Lifesciences shares in Q2 2026, an estimated $8.13K.
Edwards Lifesciences made up 0.03% of Blue Fin Capital's portfolio in Q2 2026, its #156 holding.
Blue Fin Capital first reported a position in Edwards Lifesciences in Q2 2024 and has held it in 6 quarters since.
Blue Fin Capital's Edwards Lifesciences position peaked at $238K in Q2 2024.
627 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Blue Fin Capital's 13F filing for Q2 2026, filed 4 Aug 2026.